Findings

What do systematic reviews say?

238 questions · 242 findings · 21 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 37 · 15.3%GRADE not reported 15 · 6.2%Very low 78 · 32.2%Low 52 · 21.5%Moderate 49 · 20.2%High 11 · 4.5%

Atypical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Intervention not reported

Atypical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 476 participants
Moderate

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 577 participants
High

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adults with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 500 participants
Moderate

Intervention not reported

Atypical AP vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 511 participants
Moderate

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 577 participants
GRADE not reported

Intervention not reported

Typical antipsychoticvs atypical antipsychotic · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 447 participants
GRADE not reported

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 440 participants
Moderate

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Regression rate at 6 months · women with atypical endometrial hyperplasia

It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 2.76 [0.26, 29.73]
1 study · 19 participants
Very low

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Nausea · women with atypical endometrial hyperplasia

It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 0.58 [0.28, 1.18]
1 study · 153 participants
Very low

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia

Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 2.89 [1.11, 7.52]
1 study · 153 participants
Low

Typical vs atypical antipsychotics

All‐cause mortality · delirious patients

Typical showed no clear difference in mortality compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.71 [0.82, 3.53]
4 studies · 342 participants
Moderate

Typical vs atypical antipsychotics

Length of hospital stay · delirious patients

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Typical vs atypical antipsychotics

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · delirious patients

It is very uncertain whether typical changes adverse Effects ‐ EPS compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 12.16 [0.55, 269.52]
2 studies · 198 participants
Very low

Typical vs atypical antipsychotics

Duration of delirium Days · delirious patients

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Typical vs atypical antipsychotics

Delirium resolution DRS, DRS‐R981 · delirious patients

Typical showed no clear difference in delirium resolution DRS, DRS‐R981 compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.1 [0.79, 1.52]
5 studies · 349 participants
Moderate

Typical vs atypical antipsychotics

Severity of delirium · delirious patients

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 542 participants
Moderate

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low